NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SOLARA · data 2026-11-01
Solara Active Pharma Sciences Ltd.
In plain words
Price: 18.3% below its 52-week high of ₹774.
Delivery: 39.7% of traded shares were kept for delivery over the last 10 sessions, against 41.9% over the last 60.
Latest results: a net profit of ₹28 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,535 cr |
| Net profit (last 12 months) | ₹37 cr |
| Sales growth, 3 years (yearly) | -1.6% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 41.9% (-0.1 pts in a year), pledged 52.0%, institutions 14.6%.
P/E 84.2, P/B 2.1, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE -0.6%, ROCE 5.9%, operating margin 8.4%: how much profit it earns on the money it uses.
Debt/equity 0.55, Profit growth — and sales growth -1.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-0.6%).
- Promoters have pledged 52.0% of their shares.
- Expensive on earnings (P/E 84.2).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
SOLARA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹417.34 crore, up 33.1% YoY and up 9.4% QoQ.
Net profit was ₹28.46 crore, a turn to profit from a loss a year ago and up 74.5% QoQ.
Operating margin was 18.4% (11.1% a year ago).
EPS was ₹5.92, positive against a negative EPS a year ago and up 68.2% QoQ.
SOLARA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹417.34 करोड़; पिछले साल की तुलना में 33.1% की बढ़त, पिछली तिमाही की तुलना में 9.4% की बढ़त।
शुद्ध मुनाफ़ा: ₹28.46 करोड़; एक साल पहले के घाटे से मुनाफ़े में आया, पिछली तिमाही की तुलना में 74.5% की बढ़त।
ऑपरेटिंग मार्जिन: 18.4% (एक साल पहले 11.1%)।
EPS: ₹5.92; एक साल पहले के ऋणात्मक EPS से धनात्मक हुआ, पिछली तिमाही की तुलना में 68.2% की बढ़त।
SOLARAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹417.34 કરોડ; ગયા વર્ષની સરખામણીએ 33.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 9.4% વધારો.
ચોખ્ખો નફો: ₹28.46 કરોડ; એક વર્ષ પહેલાંની ખોટમાંથી નફામાં આવી, ગયા ક્વાર્ટરની સરખામણીએ 74.5% વધારો.
ઓપરેટિંગ માર્જિન: 18.4% (એક વર્ષ પહેલાં 11.1%).
EPS: ₹5.92; એક વર્ષ પહેલાંના નકારાત્મક EPSથી હકારાત્મક થઈ, ગયા ક્વાર્ટરની સરખામણીએ 68.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 27.0% over the last 20 sessions vs 29.5% in the 40 before (0.92x); shares delivered per day 0.87x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 16 Oct 26Results Q2 FY27 results: turned to profit vs a year ago -0.5% next session
- 23 Jul 26Results Q1 FY27 results: profit +55.0% YoY -8.2% next session
- 15 May 26Results Q4 FY26 results: turned to profit vs a year ago +10.6% next session
- 6 Feb 26Results Q3 FY26 results: turned to loss vs a year ago -9.1% next session
- 6 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -8.4% next session
- 25 Jul 25Results Q1 FY26 results: turned to profit vs a year ago 0.0% next session
- 15 May 25Results Q4 FY25 results: loss narrowed vs a year ago -17.1% next session
- 24 Jan 25Results Q3 FY25 results: turned to profit vs a year ago -17.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹417 cr | ₹28 cr | — | 18.4% | 5.92 |
| Jun 2026 | ₹382 cr | ₹16 cr | +55.0% | 16.2% | 3.52 |
| Mar 2026 | ₹387 cr | ₹10 cr | — | 14.9% | 2.2 |
| Dec 2025 | ₹349 cr | ₹-17 cr | -315.5% | 10.7% | -3.98 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 41.93% | 41.93% | 42.00% | 42.00% |
| Foreign institutions (FII) | 10.71% | 11.52% | 11.59% | 11.98% |
| Domestic institutions (DII) | 3.89% | 3.74% | 3.75% | 3.64% |
| Mutual funds | 0.87% | 0.95% | 1.18% | 1.18% |
| Retail investors | 20.17% | 19.14% | 18.88% | 18.89% |
| Number of shareholders | 70,905 | 70,490 | 70,400 | 71,890 |
Common questions
What was Solara Active Pharma Sciences Ltd.'s latest quarterly profit?
Solara Active Pharma Sciences Ltd. reported a net profit of ₹28 cr for the quarter ended Sept 2026, on revenue of ₹417 cr.
How much do promoters hold in Solara Active Pharma Sciences Ltd.?
Promoters held 41.93% of Solara Active Pharma Sciences Ltd. at the end of Sept 2026, with 52.02% of promoter shares pledged.
Is Solara Active Pharma Sciences Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.55.
What is Solara Active Pharma Sciences Ltd.'s P/E ratio?
About 84.2, based on the last 12 months' earnings and a price of ₹632.6 (data 2026-11-01).
What is the 52-week high and low of Solara Active Pharma Sciences Ltd.?
The 52-week high is ₹774 and the 52-week low is ₹422.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences Ltd. | ₹632.6 | ₹3,043 cr | 84.2 | 2.1 | -0.6% | 5.9% | 0.55 | +6.1% |
| Kwality Pharmaceuticals Ltd | ₹3,475.3 | ₹3,604 cr | 44.5 | — | 22.6% | 31.4% | 0.39 | +98.9% |
| Unichem Laboratories Limited | ₹483.75 | ₹3,404 cr | 11.2 | — | 9.8% | -0.5% | 0.18 | +3.4% |
| Shukra Pharmaceuticals Ltd. | ₹74.87 | ₹3,295 cr | 96.6 | — | 28.9% | 31.3% | 0.06 | +78.1% |
| Ind-Swift Laboratories Ltd. | ₹368.2 | ₹3,195 cr | 38.2 | 2.2 | 3.4% | -0.2% | 0.01 | +260.3% |
| Hikal Limited | ₹211.58 | ₹2,601 cr | — | — | -4% | 3.1% | 0.57 | -13.1% |
Compare SOLARA with KPL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SOLARA in NSE Scanner →